Prescient Therapeutics appoints leading brain cancer specialist to advisory board
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to...
Researchers at the University of Pennsylvania (Penn) are developing a new way for cancer-fighting CAR-T...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps...
CAR-T therapies have proven to be revolutionary treatments for cancer, but their high costs have...
Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news....
Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple...
ASX-listed oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in developing a robust drug pipeline...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has announced its June 2021 results, marked by...
Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter. The clinical-stage...
In an update that endorses the potential benefits of Prescient Therapeutic’s (ASX:PTX) anti-cancer drug PTX-100,...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.